Heroix

Heroix is a Philadelphia-based biotechnology company co-founded by world-renowned CAR-T cell therapy pioneers from the University of Pennsylvania, including Dr. Carl June and Dr. Bruce Levine. The company is focused on developing next-generation chimeric antigen receptor (CAR) T-cell therapies specifically engineered to overcome the immunosuppressive barriers of the tumor microenvironment in solid tumors. By utilizing advanced cell engineering techniques, Heroix aims to enhance the persistence, infiltration, and potency of T-cells within dense tumor tissues. The startup is backed by prominent investors such as GV and Lightspeed Venture Partners and is currently advancing its pipeline through the pre-clinical stage.